Journal Article10.1200/JCO.2005.02.9488
Does Granulocyte Colony-Stimulating Factor Worsen Anemia in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide?
Paola Papaldo,Gianluigi Ferretti,Serena Di Cosimo,Diana Giannarelli,Paolo Marolla,Massimo Lopez,Enrico Cortesi,Mauro Antimi,Edmondo Terzoli,Paolo Carlini,Patrizia Vici,Claudio Botti,Luigi Di Lauro,Giuseppe Naso,Cecilia Nisticò,Marcella Mottolese,Franco Di Filippo,Enzo Maria Ruggeri,Anna Ceribelli,Francesco Cognetti +19 more
45
TL;DR: The data suggest that a G-CSF dose-related effect may play a role in worsening anemia in patients receiving adjuvant EC.
read more
Abstract: Purpose We report on the effects of granulocyte colony-stimulating factor (G-CSF) on hemoglobin (Hb) value in early breast cancer patients receiving high-dose epirubicin and cyclophosphamide (EC) adjuvant treatment. Methods Five hundred and six stage I or stage II female breast cancer patients were treated with E 120 mg/m2 and C 600 mg/m2 with or without G-CSF and randomly assigned to receive in a factorial 2 × 2 design: EC; EC + lonidamine; EC + G-CSF; EC + lonidamine + G-CSF. Five consecutive G-CSF schedules tested 100 randomly assigned patients each: (1) 480 μg subcutaneously on days 8 to 14; (2) 480 μg on days 8, 10, 12, 14; (3) 300 μg on days 8 to 14; (4) 300 μg on days 8, 10, 12, and 14; and (5) 300 μg on days 8 and 12. The mean Hb level of 246 patients receiving EC plus G-CSF was compared with that of 240 patients receiving EC alone. The data presented are derived from an exploratory hypothesis-generating analysis. Results The EC dose intensity did not statistically differ between the G-CSF and the...
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
Thomas J. Smith,Kari Bohlke,Gary H. Lyman,Kenneth R. Carson,Jeffrey Crawford,Scott J. Cross,John M. Goldberg,James Khatcheressian,Natasha B. Leighl,Cheryl L. Perkins,George Somlo,James L. Wade,Antoinette J. Wozniak,James O. Armitage +13 more
TL;DR: Current recommendations for the management of patients exposed to lethal doses of total-body radiotherapy, but not doses high enough to lead to certain death as a result of injury to other organs, include the prompt administration of CSFs.
926
Severe Malarial Anemia: Innate Immunity and Pathogenesis
Douglas J. Perkins,Tom Were,Gregory C. Davenport,Prakasha Kempaiah,James B. Hittner,John M. Ong’echa +5 more
TL;DR: The role of P. falciparum-derived Hz (PfHz) in mediating suppression of erythropoiesis through its ability to cause dysregulation in pro- and anti-inflammatory cytokines, growth factors, chemokines, and effector molecules is discussed in detail.
Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma
Hans Wildiers,Marcel Reiser +1 more
TL;DR: There is strong evidence that patients benefit from full-dose chemotherapy, with RDI reductions associated with reduced survival, and G-CSF improved the chances of higher RDI in most studies.
141
Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients
TL;DR: The strength of the evidence was weak for the majority of outcomes, which was mostly because of the small numbers of evaluable patients, varying definitions, as well as unclear measurements of the trials' outcomes and uncertain influences of supportive treatments on them.
Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03).
TL;DR: The inclusion of the 21-gene signature in Japan’s social health insurance benefit package for not only LN− diseases but also LN+ diseases is cost-effective and can be justifiable as an efficient use of finite resources for health care.
79
References
•Book
Cancer : Principles and Practice of Oncology
Vincent T. DeVita,Samuel Hellman,Steven A. Rosenberg +2 more
- 01 Jan 1982
TL;DR: Part I: Molecular Biology of Cancer Molecular Methods in Oncology Section 1. Amplification Techniques Section 2. RNA Interference Section 3. cDNA arrays Section 4. Tissue arrays Section 5. Cytogenetics Section 6. Bioinformatics Genomics and Proteomics Molecular Targets in oncology.
9.5K
Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients With Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial
Jacques Bonneterre,Henri Roché,Pierre Kerbrat,Alain Brémond,Pierre Fumoleau,Moïse Namer,Marie-Josèphe Goudier,Simon Schraub,Pierre Fargeot,Isabelle Chapelle-Marcillac +9 more
TL;DR: Treatment with adjuvant FEC 100 demonstrated superior DFS and OS versus FEC 50 at 10 years of follow-up, and was not offset by long-term complications such as cardiac toxicity and second malignancy.
289
Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium.
Janice Gabrilove,Ann A. Jakubowski,K. Fain,John Grous,Howard I. Scher,Cora N. Sternberg,Alan Yagoda,Bayard D. Clarkson,Mary Ann Bonilla,Herbert F. Oettgen +9 more
TL;DR: It is demonstrated that rhG-CSF is a potent stimulus for normal neutrophil proliferation and maturation in patients with transitional cell carcinoma before chemotherapy.
Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5
Mark Levine,Kathleen I. Pritchard,Vivien H.C. Bramwell,Lois E. Shepherd,Dongsheng Tu,Nancy Paul +5 more
TL;DR: The previously demonstrated benefit of CEF compared with CMF adjuvant chemotherapy is maintained with longer follow-up in the MA5 trial, and the rates of congestive heart failure and acute leukemia have not changed since the original report.
231
Treatment of aplastic anemia in children with recombinant human granulocyte colony-stimulating factor.
TL;DR: The study indicates that rhG-CSF will be particularly useful in managing patients with aplastic anemia complicated by bacterial or fungal infection, and that this agent is effective in stimulating granulopoiesis in children with a plastically anemia.
130
Related Papers (5)
Thomas J. Smith,James Khatcheressian,Gary H. Lyman,Howard Ozer,James O. Armitage,Lodovico Balducci,Charles L. Bennett,Scott B. Cantor,Jeffrey Crawford,Scott J. Cross,George D. Demetri,Christopher E. Desch,Philip A. Pizzo,Charles A. Schiffer,Lee S. Schwartzberg,Mark R. Somerfield,George Somlo,James C. Wade,James L. Wade,Rodger J. Winn,Antoinette J. Wozniak,Antonio C. Wolff +21 more
Paola Papaldo,Massimo Lopez,Enrico Cortesi,Eugenio Cammilluzzi,Mauro Antimi,Edmondo Terzoli,Giuseppe Lepidini,Patrizia Vici,Carlo Barone,Gianluigi Ferretti,Serena Di Cosimo,Cecilia Nisticò,Paolo Carlini,Francesca Conti,Luigi Di Lauro,Claudio Botti,Carlo Vitucci,Alessandra Fabi,Diana Giannarelli,Paolo Marolla +19 more